Skip to content

Study · Case report or series · n = 1 · 2025

2 results

Semaglutide-Associated Gastric Pneumatosis.

Turunen AM, Coombs RA, Garg SK

ACG case reports journal27 Dec 2024Cited by 4 (Europe PMC)

PMID39734391 (opens in a new tab)PMCIDPMC11671069 (opens in a new tab)DOI10.14309/crj.0000000000001579 (opens in a new tab)PepBankPUB-39734391
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Semaglutide, a glucagon-like peptide-1 receptor agonist, used for Type 2 diabetes mellitus and more recently for weight loss, often causes gastrointestinal adverse effects such as delayed gastric emptying and abdominal discomfort. Current literature has not described an associated case of gastric pneumatosis with semaglutide use. We report a 61-year-old man on semaglutide for 9 months with gastric pneumatosis. Symptoms resolved on discontinuation. Clinicians should be vigilant for significant gastrointestinal adverse effects, including pneumatosis with semaglutide use.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A 61-year-old man on semaglutide for 9 months developed gastric pneumatosis.

    In plain wordsA 61-year-old man who took semaglutide for 9 months developed gastric pneumatosis, a gas pocket in the stomach wall.

    Peptide
    Semaglutide
    Outcome
    Not applicableGastric pneumatosis
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    We report a 61-year-old man on semaglutide for 9 months with gastric pneumatosis.
  2. 02HumanCase report or seriesSafety outcome

    In a 61-year-old man with semaglutide-associated gastric pneumatosis, symptoms resolved when semaglutide was stopped.

    In plain wordsIn one man, the stomach symptoms went away after semaglutide was stopped.

    Peptide
    Semaglutide
    Outcome
    Not applicableSymptom resolution after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    Symptoms resolved on discontinuation.
    1 context sentence
    Summary · context
    We report a 61-year-old man on semaglutide for 9 months with gastric pneumatosis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.